Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 614

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 614
---
   |
| Purchase of equipment                                                                              |     |                                 |        - |   |     |      |  (2,982 | ) |
| Net cash used in investing activities                                                              |     |                                 |        - |   |     |      |  (2,982 | ) |
| Net (decrease) increase in cash                                                                    |     |                                 |  (69,483 | ) |     |      |  16,585 |   |
| Cash, beginning of period                                                                          |     |                                 |   76,957 |   |     |      |  20,644 |   |
| Cash, end of period                                                                                |     | $                               |    7,474 |   |     | $    |  37,229 |   |
| Supplemental disclosure of cash flow information                                                   |     |                                 |          |   |     |      |         |   |
| Cash paid for interest during the period                                                           |     | $                               |        - |   |     | $    |   1,630 |   |
| Cash paid for taxes during the period                                                              |     | $                               |        - |   |     | $    |       - |   |

| F-94 |

<div align='center'>CEREVAST MEDICAL, INC.

NOTES TO FINANCIAL STATEMENTS (UNAUDITED)</div>

Note 1 – Organization and Description of the Business

Description of the Business

Cerevast Medical, Inc. (“Cerevast” or the “Company”), a Delaware corporation, is a clinical-stage medical device company based in Bothell, Washington, USA. The Company is committed to developing novel, first-in-class therapeutic solutions to restore health and improve the quality of life for patients that suffer from major diseases by leveraging their core expertise in the fields of ultrasound and microsphere technologies. The Company’s lead clinical stage programs are for the treatment of ischemic stroke and retinal vein occlusion, two devastating diseases with limited treatment options that affect millions of patients worldwide each year.

Going Concern

The Company does not have any current revenues. For the nine months ended September 30, 2024, the Company realized operating loss of $1,097,141 and has an accumulated deficit as of September 30, 2024 of $22,964,024. As of September 30, 2024, the Company had $7,474 in its operating bank accounts and a working capital deficit of $1,599,